RZLT vs. CNTA, IMVT, TARS, CDTX, MOR, KNSA, MLYS, BEAM, NTLA, and HCM
Should you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include Centessa Pharmaceuticals (CNTA), Immunovant (IMVT), Tarsus Pharmaceuticals (TARS), Cidara Therapeutics (CDTX), MorphoSys (MOR), Kiniksa Pharmaceuticals International (KNSA), Mineralys Therapeutics (MLYS), Beam Therapeutics (BEAM), Intellia Therapeutics (NTLA), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.
Rezolute vs. Its Competitors
Centessa Pharmaceuticals (NASDAQ:CNTA) and Rezolute (NASDAQ:RZLT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.
In the previous week, Centessa Pharmaceuticals had 6 more articles in the media than Rezolute. MarketBeat recorded 7 mentions for Centessa Pharmaceuticals and 1 mentions for Rezolute. Centessa Pharmaceuticals' average media sentiment score of 0.77 beat Rezolute's score of 0.00 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.
Centessa Pharmaceuticals' return on equity of -40.39% beat Rezolute's return on equity.
Centessa Pharmaceuticals currently has a consensus price target of $32.38, indicating a potential upside of 40.64%. Rezolute has a consensus price target of $14.50, indicating a potential upside of 66.86%. Given Rezolute's higher possible upside, analysts clearly believe Rezolute is more favorable than Centessa Pharmaceuticals.
Centessa Pharmaceuticals has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, Rezolute has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500.
82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 7.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 14.8% of Rezolute shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Rezolute has lower revenue, but higher earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.
Summary
Centessa Pharmaceuticals beats Rezolute on 8 of the 14 factors compared between the two stocks.
Get Rezolute News Delivered to You Automatically
Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rezolute Competitors List
Related Companies and Tools
This page (NASDAQ:RZLT) was last updated on 10/19/2025 by MarketBeat.com Staff
Free RZLT Stock Alerts